Bio­equi­va­lence Waiver for Lower Strengths of a BCS Class IV Drug [Regulatives / Guidelines]

posted by dshah  – India, 2025-07-07 13:07 (357 d 08:39 ago) – Posting: # 24407
Views: 2,684

Dear Praveen!

❝ Would it be acceptable to waive in vivo bioequivalence studies for the 60 mg and 80 mg strengths? Or, given the BCS Class IV designation, are BE studies still required for each individual strength?


It will be good to evaluate it based on dissolution and not just PK linearity/dose proportionality for lower strength Biowaiver.

Divyen

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
258 visitors (0 registered, 258 guests [including 22 identified bots]).
Forum time: 21:47 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5